
Medical Device Manufacturer

Source: Siyu Medtech
On June 5, 2024, the FDA decided to recall Medtronic's (NYSE: MDT) StealthStation S8 platform software, with the recall classified as Class I. Previously, on April 1, Medtronic initiated a recall of certain versions of its StealthStation S8 application.

Following customer complaints about software errors causing missing and replacement issues with numbers or letters in displayed text, Medtronic is recalling multiple versions of the StealthStation S8 application (including versions 1.2.0, 1.1.0, 1.0.3, 1.0.2, and 1.0.1).
It is reported that due to a software error in the StealthStation S8 application, missing numbers may cause the mechanical depth limiter to be set either too short or too long. This, in turn, may lead to surgeons incorrectly placing the biopsy tip limiter during surgical navigation as a result of using inaccurate measurement data.
Performing skull surgery at an incorrect location may lead to severe permanent injuries, including brain, nerve, or cerebrovascular damage; abnormal function of the brain, spine, or muscles; paralysis; or death.
Currently, Medtronic reports28 complaints related to this issue。
There are currently no reports of casualties.
On December 19, 2023, the U.S. FDA classified Medtronic's voluntary recall initiated on September 27, 2023, as a Class I recall.

However, the FDA also pointed out that this recall only involves a software update for the navigation robot, not a product replacement. The affected software versions are StealthStation S8 2.0 and 2.0.1, as well as 2,109 navigation systems sold in the U.S. from January 7, 2022, to October 2, 2023.
The reason for the recall is a software malfunction that may cause the surgical planning data to shift position after changes to the initial test, resulting in an unintended location during surgery.
Using the affected products may lead to serious consequences, including death.
Revolutionizing Visualization Technology: Augmented Reality Platform Enhances Skull Surgery
Medtronic Stealth Station S8 is an innovative neurosurgical navigation system that integrates advanced point-surface registration technology, intelligent algorithm-based tumor contouring, multi-modal image auto-fusion technology, and electromagnetic panel technology. These technologies enable the system to track surgical tools in real time relative to the patient’s anatomy through the patient's imaging data, providing surgeons with a precise navigation tool.
The intuitive interface and ergonomic design of the Stealth Station S8 allow surgeons to operate via both touchscreen and mouse, enhancing the convenience and efficiency of procedures. The system is particularly suited for spinal surgeries, providing clear visualization of each spinal segment's detailed structure. Its seamless integration with over 200 Stealth navigation spinal instruments and implants streamlines the surgical workflow.
Key features of the system include:
Preset trajectory projection helps doctors plan the movement path of tools before surgery.
Adjust the transparency of surgical tools to optimize the visualization of the surgical area.
Pre-select implants during the surgical procedure and quickly access surgical tools.
Integrated with the O-arm O2 Imaging System, it reduces reliance on intraoperative fluoroscopy and lowers radiation exposure risks for surgeons and staff.
In 2021, Medtronic announced a partnership with Surgical Theatre, a market leader in VR/AR healthcare services, to provide an augmented reality platform for skull surgeries.

Treating brain tumors, aneurysms, and neurological disorders ranks among the most risky and complex surgical procedures. Real-time access to the most detailed patient-specific information, such as the spatial relationships between vascular structures, arteries, and white matter locations, is crucial.
Medtronic to Connect Stealth Station S8 Surgical Navigation System with Surgical Theatre's SyncAR Technology, Bringing 360° Rendered AR Overlays into Cranial Surgeries to Enhance Neurosurgeons' Visibility During Procedures.
SyncAR technology aims to allow surgeons, before entering the operating room, to visualize brain structures, test virtual surgical tools, and plan surgeries through rehearsal simulation technology.
The StealthStation S8 is designed to track surgical instruments and guide users during procedures through hardware and clinical software that incorporate tracking and image dataset merging algorithms.
Both parties indicated that the combination of StealthStation S8 + SyncAR is expected to enhance the precision and efficiency of complex cranial surgeries, allowing surgeons to visualize previously hidden anatomical and vascular structures, pathology, and diffusion tensor imaging.
Medtronic is a global leading medical technology company, established in 1949, with its headquarters located in Minnesota, USA. Medtronic's main product lines include four major businesses: cardiovascular, surgical and critical care, neuroscience, and diabetes, covering products and service systems in the treatment areas of arrhythmia, heart failure, cardiac intervention, heart valve replacement, diabetes, gastrointestinal diseases, urological diseases, spinal diseases, neurological disorders, and ENT.
As a technology company, Medtronic is also committed to researching and developing new medical technologies to improve patients' quality of life. The company has numerous R&D centers and production bases worldwide, with a total workforce of over 90,000 employees. Medtronic's business spans more than 150 countries and regions globally.
On May 23, 2024, Medtronic released its latest financial report. The total revenue in 2023 was $31.227 billion (approximately 224.8 billion RMB), with a net profit margin of 12%. Its sales volume ranked second in the global medical device market.
This article is reprinted, all opinions belong to the original platform (Siyu MedTech). Medical Device Business Review remains neutral on all views in the article and is only for sharing and communication.